Perth, Jan 24, 2025 AEST (ABN Newswire) – Proteomics International Laboratories Ltd (ASX:PIQ) Managing Director Dr. Richard Lipscombe is Interviewed about the Promarker Suite of Diagnostic Tests.
In this interview, Dr. Lipscombe explains the PromarkerD, PromarkerENDO, PromarkerESO and OxiDx diagnostic tests that considerably reduce the cost to patient and health care systems by providing a simple blood test replacing otherwise invasive surgery.
Dr. Lipscombe also details the commercial model for the global access to these tests using a “traditional” and “hybrid” approach.
First sales of the predictive diagnostic tests are due first quarter 2025.